Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015


Cite item

Full Text

Abstract

Mineralocorticoid receptor antagonists (MCRA) are part of standard medical therapy for heart failure (HF). The clinical efficacy of MCRA in patients with systolic HF has been proven by randomized clinical trials. The efficacy of this drug group in patients with chronic HF with preserved left ventricular systolic function and the advent and practical introductions of safer new-generation MCRA remain to be answered.

References

  1. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012;33:1787-1847.
  2. Jessup M, Abraham WT, Casey DE et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977-2016.
  3. McMurray JJ, Adamopoulos S, Anker SD et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803-869.
  4. de Gasparo M, Joss U, Ramjoue HP et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol ExpTher. 1987;240:650-656.
  5. Delyani J, Myles K, Funder J et al. Eplerenone (SC 66110), a highly selective aldosteron antagonist. Am J Hypertens. 1998; 11:94A.
  6. Gardiner P, Schrode K, Quinlan D et al. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol. 1989;29:342-347.
  7. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008;31:153-158.
  8. Michea L, Delpiano AM, Hitschfeld C et al. Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology. 2005;146:973-980.
  9. Degasparo M, Joss U, Ramjoué HP, Whitebread SE, Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, Grob J, Schmidlin J et al. Three new epoxy-spironolactone derivates: characterization in vivo and in vitro. J PharmacolExp Ther. 1987,240:650-656.
  10. Cook CS, Berry LM, Kim DH et al. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos. 2002;30(12):1344-1351.
  11. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15(8):709-716.
  12. Sadee W, Dagcioglu M, Schroder R. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J Pharmacol Exp Ther. 1973;185(3):686-695.
  13. Pitt B, Zannand F, Remme W et al. The effect of spirinilactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
  14. Pitt B, Roniker B. Eplerenone, a novel selective aldosteron receptor antagonist (SARA): dose-finding study in patients with heart failure. J Am CollCardiol. 1999;33:188A-189A.
  15. Zannad F, McMurray JJV, Drexler H et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail. 2010;12(6):617-622.
  16. Zannad F., McMurray JJV, Krum H. et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med. 2011;364:11-21.
  17. Swedberg K, Zannad F, McMurray JJ et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol. 2012;59(18):1598-1603.
  18. Pitt B, Remme W, Zannad F et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med. 2003;348:1309-1321.
  19. Zannad F, Gattis StoughW, Rossignol P et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012;33:2782-2795.
  20. Chatterjee S, Moeller C, Shah N, Bolorunduro O, Lichstein E, Moskovits N, Mukherjee D. Eplerenone is not superior to older and less expensive aldosterone antagonists. Am J Med. 2012;125:817-825.
  21. Hernandez AF, Mi X, Hammill BG et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA. 2012;308:2097-2107.
  22. Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ. 2011 update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. Med J Aust. 2011;194:405-409.
  23. McKelvie RS, Moe GW, Cheung A et al. Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. Can J Cardiol. 2011;27:319-338.
  24. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670-679.
  25. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation. 2004;110(5):558-565.
  26. Degasparo M, Joss U, Ramjoue et al. Three new epoxy-spironolactone derivates: characterization in vivo and in vitro. J Pharmacol ExpTher. 1987,240:650-656.
  27. Cook CS, Berry LM, Kim DH et al. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos. 2002;30(12):1344-1351.
  28. Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail. 2011;17(8):634-642.
  29. Edelmann FWR, Schmidt AG et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: The Aldo-DHF randomized controlled trial. JAMA. 2013;309(8):781-791.
  30. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol. 2001;37: 1800-1807.
  31. Beck L, Blanc-Guillemaud V, Cherif OK, Jover B, Davy JM. Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction. Cardiology. 2001;96:85-93.
  32. Fletcher J, Buch AN, Routledge HC, Chowdhary S, Coote JH, Townend JN. Acute aldosterone antagonism improves cardiac vagal control in humans. J Am Coll Cardiol. 2004;43:1270-1275.
  33. Wei J, Ni J, Huang D, Chen M, Yan S, Peng Y. The effect of aldosterone antagonists for ventricular arrhythmia: a meta-analysis. Clin Cardiol. 2010;33:572-577.
  34. Rose LI, Underwood RH, Newmark SR, Kisch ES,Williams GH. Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med. 1977;87:398-403.
  35. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839-845.
  36. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002; 15:709-716.
  37. Parthasarathy HK, Menard J, White WB, Young WF Jr, Williams GH, Williams B, Ruilope LM, McInnes GT, Connell JM, MacDonald TM. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29:980-990.
  38. Karagiannis A, Tziomalos K, Papageorgiou A et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. ExpertOpin Pharmacother. 2008;9:509-515.
  39. Danjuma M I, Mukherjee I, Makaronidis J et al. Converging Indications of Aldosterone Antagonists (Spironolactone and Eplerenone): A Narrative Review of Safety Profiles. Curr Hypertens Rep. 2014;16:414.
  40. Iqbal J, Parviz Y, Pitt B et al. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. Eur J Heart Fail. 2014;16:143-150.
  41. Maron BA, Leopold JA. Aldosterone receptor antagonists: effective but often forgotten. Circulation. 2010;121:934-939.
  42. Albert NM, Yancy CW, Liang L et al. Use of aldosterone antagonists in heart failure. JAMA 2009;302:1658-1665.
  43. Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:147-239.
  44. Chamsi-Pasha MA, Dupont M, Al Jaroudi WA et al. Utilization pattern of mineralcorticoid receptor antagonists in contemporary patients hospitalized with acute decompensated heart failure: a single-center experience. J Cardiac Fail 2014;20:4:229-235.
  45. Tebbe U, Tschöpe C, Wirtz JH et al. Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. Clin Res Cardiol. 2014;103:665-673.
  46. Böhm M, Tschöpe C, Wirtz JH et al. Treatment of heart failure in real-world clinical practice: findings from REFLECT-HF Registry in patients with NYHA class symptoms and a reduced ejection fraction. Clin Cardiol. (in press) 2015:1-7.
  47. Yamaji M, Tsutamoto T, Kawahara C et al. Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress. Circ Heart Fail. 2009;2: 608-615.
  48. Yamaji M, Tsutamoto T, Kawahara C et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1(c) levels in patients with chronic heart failure. Am Heart J. 2010;160:915-921.
  49. Fagart J, Hillisch A, Huyet J et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010;285:29932-29940.
  50. Pitt B, Filippatos G, Gheorghiade M. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail. 2012;14:668-675.
  51. Barfacker L, Kuhl A, Hillisch A et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. Chem Med Chem. 2012;7:1385-1403.
  52. Pitt B, Kober L, Ponikowski P et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34:2453-2463.
  53. Pitt B, Anker SD, Böhm M et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail. 2015;17:224-232.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies